Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Kimberly Blackwell, will engage in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Kimberly Blackwell, will engage in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET. This event highlights Zentalis's ongoing commitment to developing small molecule therapeutics targeting cancer pathways. A webcast will be available via the company's website, offering insights into their innovative oncology pipeline, which includes notable candidates like ZN-c3 and ZN-d5.
Details
News Market Reaction – ZNTL
The recorded move for ZNTL in the trading session of this news was +0.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.
A webcast will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, Ltd., to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Investor Contact:
Adam D. Levy, PhD, MBA
Senior Vice President, Investor Relations
alevy@zentalis.com
Alexandra Roy
Solebury Strategic Communications
aroy@soleburystrat.com
Media Contact:
Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.